Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit’s® nephrology indication

  • Sandoz’ epoetin alfa product offering has already generated more than 400,0001 patient years of experience worldwide

  • EC approval expands Sandoz biosimilar offering to the healthcare community

Holzkirchen, 08 April, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication*.

“By expanding our …

/by

Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit’s® nephrology indication

  • Sandoz’ epoetin alfa product offering has already generated more than 400,0001 patient years of experience worldwide

  • EC approval expands Sandoz biosimilar offering to the healthcare community

Holzkirchen, 08 April, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication*.

“By expanding our …

/by